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Obesity continues to be one of the most common 
prevalent chronic diseases worldwide with recent data 
stating that it has now reached global pandemic 
proportions making it a major public health problem. In 
2008 the World Health Organisation (WHO) stated that 
worldwide around 1.4 billion adults were overweight 
(body mass index [BMI] 25.0-29.9 kg/m2) and a further 
500 million were obese (BMI ≥30 kg/m2). Of note, the 
prevalence of obesity has tripled in Europe over the last 
30 years with around 50% of the population in the 
majority of European countries being overweight or 
obese.1-4  Locally, the situation is also alarming with data 
from the European Health Interview Survey (EHIS) in 
2011 stating that Malta had the highest rate of obese males 
in Europe (24.7%) and when it comes to females, Maltese 
women were the second most obese after British women 
(21.1% and 23.9% respectively).5  Even more worrisome 
is the fact that Malta also tops the charts for the highest 
prevalence of overweight and obesity in school-aged 
children thus accentuating the fact that urgent action needs 
to be taken in order to tackle effectively this world-wide 
epidemic.6 Unfortunately obesity is strongly linked to 
several co-morbid conditions such as type 2 diabetes, 
hypertension, cardiovascular disease, dyslipidaemia, 
obstructive sleep apnoea, non-alcoholic steatohepatitis, 
osteoarthrosis, as well as some cancers (including breast, 
ovary, prostate, endometrium and colon) and psychiatric 
illnesses and thus it stands to reason that an increase in 
prevalence of obesity has also led to an increase in 
prevalence of these co-morbidities resulting in an 
impaired overall quality of life and decreased life 
expectancy  in these subjects.7-10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In view of the heavy burden obesity is posing on 
health-care systems worldwide, several medical and 
surgical societies have put forward guidelines on how one 
should best manage such patients.11-16 Unfortunately, the 
non-surgical options available for the treatment of obesity 
(including dietary modification enhanced physical 
activity, behavioural modification and drug treatment) do 
not lead to sustained weight loss over the long-term.  On 
the other hand, bariatric surgery is proving to be the only 
evidence-based method for inducing weight loss as well as 
resolving or improving major obesity-associated co-
morbidites.7-11,16 The Swedish Obese Subjects Study, (a 
prospective nonrandomized study involving at total of 
4047 obese subjects) found that at 2- and 10- year follow-
up both recovery and incidence rates of diabetes, 
hypertriglyceridemia and hyperuricemia were more 
favourable in the surgically treated group then in the 
control (medically treated) group. Moreover, at 10 year 
follow-up the surgically treated subjects exhibited greater 
weight loss, increased physical activity and lower energy 
intake then controls.12,17 This same study also looked at 
overall mortality 10 years after bariatric surgery and 
demonstrated a hazard ratio of 0.71.5,18  Furthermore, a 
recent paper from this ongoing study looked at the effects 
of bariatric surgery on cardiovascular events and found 
that over a median follow-up of 14.7 years surgically 
treated subjects had a reduced number of cardiovascular 
deaths and a decreased incidence of cardiovascular events 
(including myocardial infarction or stroke).5, 19  
  Thus, it is not surprising therefore, that the total 
number of bariatric surgery procedures performed 
worldwide is increasing, with nearly 350 thousand 
procedures performed globally in 2008.20-22  Bariatric 
procedures have been traditionally classified according to 
their physiologic mechanism of action namely: restrictive 
(adjustable gastric band, sleeve gastrectomy and vertical 
banded gastroplasty) malabsorptive (biliopancreatic 
diversion and duodenal switch) and those that have both a 
restrictive and malabsorptive component (Roux-en-Y 
gastric bypass). Although bariatric surgery can be 
performed using both the open or laparoscopic approach, 
the latter modality is proving to be more popular with over 
90% of bariatric surgeries being performed 
laparoscopically in 2008.21-23 Of note, the procedure 
leading to greatest excess weight loss is the 
biliopancreatic diversion/duodenal switch (diversionary 
procedures) and the least is for banding procedures 
(purely restrictive). 9-10, 20  
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 Increased understanding of the multiple hormonal 
alterations which occur following different surgical 
approaches to obesity is providing new insight into the 
more plausible hormonal mechanisms responsible for the 
control of appetite and weight loss as well as 
improvement in glycemic control then the putative 
mechanical ones which inspired the different bariatric 
techniques.24 Several studies have repeatedly confirmed 
that bariatric surgery is associated with better glycemic 
control then conventional (medical) therapy and that 
amelioration in carbohydrate metabolism frequently 
precedes weight loss and often occurs within days of the 
bariatric procedure. 25-28 It is now known that homeostatic 
alterations of certain gastrointestinal hormones - notably 
the incretin hormones glucagon-like peptide-1 (GLP-1) 
and glucose-dependent insulinotropic polypepide (GIP) 
are the main contributory factors towards the 
improvement in diabetes control following bariatric 
operations.  The reason for this has been postulated to be 
the sustained increase in release of GLP-1 from the L-
cells of the distal small intestine which occurs following 
procedures where nutrient flow bypasses the duodenum 
and proximal jejunum such as the Roux-en-Y gastric 
bypass.  The incretin effects of GLP-1 include enhanced 
insulin release and islet cell mass and improved insulin 
sensitivity all of which promote normal plasma glucose, 
plasma insulin and glycated haemoglobin levels following 
surgery..29   Furthermore, GLP-1 has also been implicated 
in the regulation of appetite such that it induces early 
satiety and thus reduces food intake. 29   Another important 
gut hormone implicated in appetite control is the 
orexigenic hormone ghrelin. Ghrelin is a peptide hormone 
which is secreted from the stomach and upper intestine in 
the pre-prandial phase and is suppressed rapidly following 
food ingestion. Studies have shown conflicting results 
with respect to plasma ghrelin levels following bariatric 
surgery with some stating there is a decreased, similar or 
even increased level 24 hours following gastric bypass 
surgery.24 The reasons for such heterogeneity in these 
results remain yet to be elucidated, however, interestingly 
diabetic patients often exhibit reduced suppression of 
post-prandial ghrelin release which may delay the onset of 
satiety. Thus, the varied spectrum of altered baseline and 
postprandial gut hormone profile which occurs following 
certain bariatric procedures is currently under intense 
scrutiny with the aim being to search for novel medical or 
surgical treatment modalities for refractory morbid 
obesity.  
Hence, in order to ensure the best possible surgical 
outcomes, the bariatric patient must be selected carefully 
and undergo a rigorous preoperative assessment to assess 
suitability for surgery.  Currently the clinical guidelines 
endorsed by different societies (including British, 
Scottish, American and European guidelines) generally 
state that patients should be considered for bariatric 
surgery if they have a BMI ≥40 kg/m2 or a BMI≥ 35 
kg/m2 with one or more obesity related co-morbidity 
which is expected to improve following surgically 
induced weight loss.7-12  Recently there has also been 
some published data demonstrating the benefits of 
bariatric surgery in mild to moderate obese patients (BMI 
30–34.9 kg/m2) in terms of weight loss and 
cardiometabolic improvements.  One randomised 
controlled study stated that subjects with mild to moderate 
obesity undergoing laparoscopic adjustable gastric 
banding had better outcomes with regards to weight loss 
and resolution of features of the metabolic syndrome then 
their non-surgically treated counterparts.11, 31-33  This has 
led to the US Food and Drug Administration (FDA) to 
approve the use of laparoscopic banding in patients with 
mild to moderate obesity and an obesity-related co-
morbidity.11, 34 However, further well designed studies are 
needed with longer follow-up periods to further assess the 
long term risk/benefit ratio of surgery in this cohort of 
patients.11 
Another area of interest is the age cut-off used by 
different bariatric programs. Although some authors state 
that advanced age (≥45 years) is associated with increased 
perioperative morbidity and mortality, in the Longitudinal 
Assessment of Bariatric Surgery (LABS) Consortium, age 
was not significantly associated with adverse 
outcomes.30,35 Moreover in another study, elderly age (≥ 
65) did not pose any limitations and led to sustained 
weight loss and improvement in quality of life with a 
negligible mortality rate and acceptable morbidity 
profile.11, 13, 15, 36 
Prior to surgery, the potential candidate must have a 
comprehensive interdisciplinary assessment ideally 
involving a specialist bariatric physician and surgeon as 
well as a dietician, psychologist or psychiatrist and a 
social worker.11-16 In the preoperative evaluation one 
should try to get a detailed medical, psychosocial and 
nutritional history.11-12, 16, 21, 24 The medical history should 
include a weight history including previous attempts at 
weight loss and previous management strategies as well as 
a family history of obesity.  One should also ask for any 
symptoms suggestive of co-morbidities such as a history 
of snoring or daytime somnolence for obstructive sleep 
apnoea or a history of shortness of breath or chest pain for 
cardiovascular disease and so forth.  One should also 
consider asking for any symptoms that could suggest a 
secondary cause for obesity (such as symptoms relating to 
hypothyroidism, Cushing’s syndrome or polycystic ovary 
syndrome [PCOS]) if indicated. Furthermore a nutritional 
history should be pursued including eating habits, the 
types of food eaten as well as triggers for eating and 
activity levels.11  A detailed psychological evaluation is 
important as unidentified underlying psychiatric illnesses 
might interfere with giving informed consent and also 
might influence the type of bariatric surgery to be 
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performed.21  It has been stated that patients with a strong-
obsessive compulsive component would not be suitable 
for gastric banding as this procedure requires co-operation 
and self control on the part of the patient.21  During this 
preoperative encounter, one is also able to assess the 
willingness and motivation of the patient and their 
potential to adhere to long term follow-up especially with 
regards to dietary recommendations and behavioural 
modifications that are required after surgery. 12, 16  At this 
point one can also evaluate the patients’ expectations as 
well as the risks/benefits of surgery including discussion 
about the different procedures available and choice of 
surgical intervention, potential complications as well as 
perioperative mortality (table 1). The candidate should 
also be made aware of patient support groups and to 
enquire about support from family members.  It is thought 
that patients who do not have long-term family support 
fare much worse than patients who have support from 
family members.10, 16 
The physical examination should include weight and 
the BMI as well as a comprehensive systemic exam.  One 
should look out for signs suggestive of a secondary cause 
of obesity such as features of Cushing’s syndrome or 
hypothyroidism or signs suggestive of the presence of co-
morbidities such as hypertension, cardiac failure, arthritis, 
evidence of diabetic retinopathy or neuropathy, acanthosis 
nigricans, eruptive xanthomata and so forth.  
Laboratory investigations should be carried out as for 
any other major abdominal surgery, however, further tests 
should be directed according to the findings on history 
taking and physical examination. Thus one should screen 
the patient for the presence of co-morbidities including 
diabetes (fasting plasma glucose or HBA1C), 
hyperlipidemia or non-alcoholic steatohepatitis (liver 
function tests and clotting studies).  Hormonal evaluation 
should be carried out if one suspects a secondary 
(endocrine) cause for obesity (such as thyroid function 
tests, 24-hour urine free cortisol or androgens if 
suspecting PCOS). Nutrient screening including iron 
studies as well as folate, vitamin B12 and vitamin D levels 
should be obtained especially if the patient will undergo 
malabsorptive procedures.11, 16 Baseline cardiopulmonary 
testing including a chest x-ray and an electrocardiogram 
should be undertaken with further investigations carried 
out as prompted by the history and physical exam.11 
The most recent guidelines (issued by the American 
Association of Clinical Endocrinologists [ACCE], The 
Obesity Society [TOS] and the American Society for 
Metabolic and Bariatric Surgery [ASMBS]) go further to 
discuss the elements which will lead to ‘medical 
clearance’ for bariatric surgery. In it they discuss certain 
issues which could influence the outcome of surgery in 
the bariatric patient.11  
 Pre-operative weight loss has been debated over the 
past few years.  Some studies have shown that 5% excess 
body weight loss is associated with beneficial short term 
outcomes including  shorter operative times, reduced 
hospital stay and higher post-operative weight loss.7, 11 37    
. However one French study did not find any 
relationship between pre and postoperative weight loss, 48 
months after surgery.38   Some studies have also described 
that preoperative weight loss leads to a reduction in liver 
size as well as intrahepatic fat and abdominal wall depth 
facilitating operative technique.  However, there is no 
conclusive evidence with regards to preoperative weight 
loss on long-term outcomes.  On the other hand it has 
been thought that preoperative weight loss will help with 
improving and optimizing glycemic control preoperatively 
as well as promote patient compliance and better chance 
of diabetes remission in the postoperative period.7, 11 
Another important aspect in patient preparation prior 
to surgery is evaluation of obstructive sleep apnoea 
(OSA).  A significant number of patients may have 
undiagnosed sleep apnea, however a good medical history 
and physical examination should alert the clinician to 
screen for OSA with polysomnography studies and if 
positive further tests such as spirometry and 
echocardiography should be undertaken.  Preoperative 
treatment entails using continuous positive airway 
pressure and postoperatively, the majority of patients 
experience resolution or improvement in their symptoms.7, 
10-11 
There have also been some studies regarding 
preoperative evaluation of the gastrointestinal tract. Some 
centres advocate routine screening with preoperative 
upper gastrointestinal (UGI) endoscopy in such patients.7, 
39 The rationale for this stems from the fact that following 
gastric bypass, evaluating of the UGI tract may be 
problematic.  One study stated that significant 
pathological findings of the UGI tract were found in 
nearly 80% of patients but only 20% had reported 
symptoms.40 In another study by UGI tract screening 
resulted in low yield for anatomical findings with UGI 
tract symptoms also not correlating with the endoscopic 
findings.39  Preoperative Helicobacter pylori screening is 
also controversial with some authors reporting lower 
incidences of postoperative marginal ulcers and others 
saying such ulcers were related to surgical technique and 
not due to H. pylori exposure.7, 11  Further randomised 
controlled studies are needed in this area, however 
endoscopic screening should be considered in high risk 
patients as it might alter surgical strategy.11, 40
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Table 1:  Overview of the current bariatric procedures performed including a comparison of efficacy, complication and 
mortality rates. 
Adapted from L. Vu et al. Best Practice & Research Clinical Endocrinology & Metabolism, 2013; 27: 239-246. 
a Weight loss is expressed in terms of excess body weight (EBW).  EBW = current weight – expected body weight based on 
height and gender. Percentage excess weight loss (EWL) is calculated as (weight loss/excess weight) x100. 
 
Type of 
bariatric 
surgical 
procedure 
Adjustable Gastric 
Banding 
Roux-en-Y Gastric 
Bypass 
Sleeve 
Gastrectomy 
Biliopancreatic Diversion 
and duodenal switch 
Procedure An inflatable silicon band is 
placed in the proximal 
portion of the stomach to 
create a pouch which can 
be adjusted to allow 
tailoring of the stoma 
outlet leading to  decreased 
meal capacity and rate of 
emptying of pouch. 
 
 
 
 
 
 
 
 
The stomach is reduced to a 
gastric pouch of around 30mL 
in size which is then 
anastomosed to the distal 
jejunum via a roux limb of 
around 100cm. The 
remaining distal end of 
stomach and proximal small 
intestine are drained via a 
bilipancreatic limb.  These 2 
limbs eventually anastomose 
further down in the small 
intestine to create the roux-
en-Y. 
 
Around 75% of the stomach 
is resected along the 
greater curvature with the 
open edges attached 
together using surgical 
staples. This creates a 
narrow gastric tube along 
the lesser curve limiting 
intake and also removing 
most of the ghrelin-
producing cells of the 
gastric mucosa. 
 
 
 
 
The gastric reservoir is reduced 
by excising 75% of the stomach 
creating a gastric sleeve. The 
small intestine is then divided 
in two places – at the 
duodenum and ileum such that 
the proximal end of ileum is 
connected to proximal part of 
duodenum thus bypassing a 
significant amount of small 
bowel and the remaining distal 
end of duodenum is 
reconnected in the ileum. 
 
 
 
Effect on 
weight 
Excess weight lossa at 5 
years ranges between 
45.4% - 48%. 8,10,21,23 
Excess weight lossa ranges 
between 60 – 70% 5 years 
after procedure. 8,10,21,23 
Excess weight lossa at 1-3 
years post surgery is 
comparable to gastric 
bypass surgery and ranges 
between 55-66%.10,21,23 
This procedure is associated 
with 70.1% excess weight loss a 
– the most effective operation 
at inducing weight loss.10,23 
Effect on type 2 
diabetes 
Resolution of type 2 
diabetes occurs in 
approximately 56% of 
patients 2 years after 
procedure.9-10,21,23 
Diabetes remission occurs in 
around 80% of patients 2 
years following surgery.9-
10,21,23 
Diabetes remission occurs 
in around 66% of 
patients.21,23 
Diabetes resolution is highest 
with this procedure with 
remission rates of around 95% 
at 2 years.10,23 
Complication 
and mortality 
rates 
This procedure is 
considered to be the safest 
with literature data stating 
an operative mortality rate 
of between 0.05 to 0.1%. 
However, mechanical 
complications can arise at a 
rate of 11.6% including 
outlet obstruction, band 
slippage or band erosion 
requiring reoperation. 
10,21,23 
Earliest complications include 
anastomotic or staple line 
leak (incidence rate 0.4 to 
5.2%). Other complications 
include marginal ulcers, 
bowel obstruction, internal 
hernia dumping syndrome 
and roux limb ischemia. Late 
complications include 
nutrient deficiencies (vitamin 
B12, folate, iron). Operative 
mortality is low with reported 
rates up to 0.5%.9-10,21,23, 
Early complications include 
bleeding and ischemia 
followed by postoperative 
gastroesophageal reflux.  
Nutritional deficiencies 
(including vitamin D, 
calcium and iron) occur 
with variable rates.  
Operative mortality is 
reported as being   0.33 
±1.6%. 21,23 
This procedure is associated 
with the highest rate of both 
early (operative) and long term 
complications such as  
anastomotic leaks and 
micronutrient deficiencies 
(including calcium and vitamin 
D deficiency) respectively. This 
procedure is also linked with 
the highest rate of 
perioperative mortality at a 
rate of 1.1%.9-10,23 
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As stated previously a thorough psychosocial–
behavioural evaluation should be carried out especially if 
the patient has a previous history of psychiatric illness or 
substance abuse/ dependence.  The European guidelines 
and several other authors state that uncontrolled 
psychiatric disorders as well as drug dependencies are 
specific contraindications for bariatric surgery as this may 
interfere with the consent process and may also impair the 
patients’ adherence to post-operative follow up.7, 9-10, 16, 21  
The Scottish guidelines on the other hand state that such 
disorders should not be considered as absolute 
contraindications.13 Thus, constant psychological support 
should be available both preoperatively as well as in the 
postoperative phase for such patients.  
Another important issue is monitoring for 
micronutrient and vitamin deficiencies.  The majority of 
obese patients are known to be deficient in vitamin D 7, 41 
as well as  vitamin A 42 and some other micronutrients 
such as ferritin and iron (more so in women).7, 42 
Appropriate preoperative measurements especially if the 
patient will undergo extensive malabsorptive procedures 
are prudent and micronutrient or multivitamin 
supplementation should be provided where necessary.7, 
11,13  
Finally, the choice of surgical procedure must be 
made jointly by the patient and the bariatric surgeon, 
taking into account all the above factors as well as the 
experience of the surgeon and the facilities and equipment 
available. 7, 11-12, 16 
As one can see bariatric surgery in the carefully 
selected obese patient, remains superior to any other 
nonsurgical forms of treatment for weight loss and 
improvement in surrogate markers of metabolic disease.  
However, further properly designed randomised 
controlled studies are needed to assess long-term benefits 
and durability of such outcomes.  
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